Successful desensitization to brentuximab vedotin after hypersensitivity reaction

Journal of Drugs in Dermatology

Volumn 13, Issue 6, 2014, Pages 749-751

  Story, Sara K ^a   Petrov, Andrej A ^b   Geskin, Larisa J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; ANTIBODY CONJUGATE; CAC10-VCMMAE;

ADULT; ARTICLE; CASE REPORT; DESENSITIZATION; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MYCOSIS FUNGOIDES; RETREATMENT; IMMUNOLOGY; PROCEDURES; SKIN NEOPLASMS;

DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; IMMUNOCONJUGATES; MIDDLE AGED; MYCOSIS FUNGOIDES; SKIN NEOPLASMS;

EID: 84903376396     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Reichert JM. Which are the antibodies to watch in 2013? MAbs. 5:1-4, 2013
2. Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol. 7:55-63, 2011
3. Hong DI, Bankova L, Cahill KN et al. Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies. Expert Rev Clin Immunol. 8:43-52; quiz 53-4, 2012
4. Pro B, Advani R, Brice P et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 30:2190-6, 2012
5. SeattleGenetics: Adcetris: Highlights of Prescribing Information. http://www.adcetris.com/pdf/ADCETRIS-Prescribing-Information.pdf, accessed April 10, 2013
6. Buss NA, Henderson SJ, McFarlane M et al. Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol. 12:615-22, 2012
7. Nissim A, Chernajovsky Y. Historical development of monoclonal antibody therapeutics. Handb Exp Pharmacol. 3-18, 2008